The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy.

Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

Jacksonville, FL

Pharmacology Translational Unit

Ocala, FL

Indianapolis, IN

Troy, MI

New York, NY

Ontario, Canada

Bay City, MI

Hollywood, FL

Fredericton, Canada

San Antonio, Texas

Albuquerque, NM

San Juan, PR

Litchfield Park, AZ

Calgary, Canada

 Edmonton, Canada

Encinitas, CA

Fountain Valley, CA

Los Angeles, CA

Lilly

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to severe atopic dermatitis and have completed a qualifying parent study. The efficacy and safety of two dosage strengths of Abrocitinib, 100 mg and 200 mg taken orally once daily, will be evaluated over variable lengths of study participation. The study consists of a 92 week initial treatment period followed by a variable length secondary treatment period during which subjects will receive treatment with open-label abrocitinib until availability of commercial product in their country, or until the sponsor terminates the study in that country.

The B7451015 study also includes a sub-study evaluating whether abrocitinib has any potential effects on adolescent bone with regard to abnormal bone findings in knee MRI. The sub-study will be conducted in selected countries at selected sites. Eligible subjects are those who were 12 to \<18 years of age at the screening visit of the qualifying parent study and who are currently participating in the main B7451015 study. The sub-study will include serial Magnetic Resonance Imaging (MRI) annually and continue until all enrolled subjects are 18 years of age and have been imaged at least once or have discontinued/withdrawn.

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Shelby, NC

Greensboro - Cardiology

Norfolk, VA

Rockville, MD

Bexley, OH

White Marsh, MD

Owensboro, KY

Plainfield, IN

Tampa, FL

Derm Center

Clarkston, MI

Forest Hills Dermatology Group

London, Canada

UR Dermatology at College Town

Normal, IL

Oakvile, Canada

Mississauga, Canada

Toronto, Canada

Richmond Hill, Canada

Ontario, CA

Boca Raton, FL

Barrie, Canada

Miami Lakes, FL

Clinical Research Site

Miami, FL

Sudbury, Canada

Clinical Operations Department

Saint Joseph, MO

Clinique Medicale Saint-Louis

Minneapolis, MN

Arlington, TX

Pflugerville, TX

San Antonio, TX

Merida, Mexico

Monterrey, Mexico

Rapid City, SD

Veracruz, Mexico

JM Research SC

St. Johns, NL

Edmonton, AB

Spokane, WA

San Diego, CA

HQ, Irvine, CA

Santa Monica, CA

Portland, OR

Sheffield Children's Hospital - Clinical Research Facility

Clinical Research Unit

Wroclaw, Poland

Krakow, Poland

Maroubra

East Melbourne, Australia

Carlton, Australia

Pfizer

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD.

Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This study is conducted in 2 periods. During Period 1, participants are randomly assigned into 1 of 2 groups called treatment arms to receive upadacitinib Dose A or dupilumab Dose A. Based on the participants response to upadacitinib Dose A, they may have their dose increased to upadacitinib Dose B after 2 weeks. In Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 300 adult participants ages 18 to 64 with moderate to severe AD who are current users of dupilumab and had a history of inadequate response to dupilumab will be enrolled at up to 94 sites worldwide.

The study is comprised of a 35-day Screening Period, an 8-week Open-Label Period 1 and a 24-week Open-Label Period 2 for participants that completed Period 1. Participants will receive upadacitinib oral tablets once daily or dupilumab subcutaneous (SC) injection every other week for 32 weeks and followed for 30 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Dawsonville, GA

Plymouth Meeting, PA

West Lafayette, Indiana

Coral Springs - Oncology

Margate, FL

Quincy, MA

Plano, TX

Dallas, TX

Bellaire, TX

Cypress, TX

Lincoln, NE

Austin, TX

Boise, ID

 Thousand Oaks, CA

Sacramento, CA

AbbVie

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Charlotte, NC

Internal Medicine Glennan Center for Geriatrics and Gerontology

Towson, MD

Jose Garcia, Coordinator

Hamilton, Canada

SLUCare Academic Pavilion - Endocrinology Division Research

Waterloo, Canada

Newmarket, Canada

North Little Rock

Hialeah, FL

Hot Springs, AR

Ottawa, Canada

Dermatology and Skin Cancer Center Leawood

Texas Medical Center

McGovern Medical School - ACTAT - Research Department

Research Center

Saskatoon, Canada

Scottsdale, AZ

Las Vegas, NV

Long Beach, CA

Northridge, CA

Canoga Park, California

Bakersfield, CA

Reno - Moana Lane Location

Kelowna, Canada

Dublin, CA

Clinical Research Institute of Southern Oregon (CRISOR)

Maldegem, Belgium

Remscheid, Germany

Hannover, Germany

Haematology Department

Clinical Trial Center

Tartu, Estonia

Santiago, Chile

Szolnok, Hungary

Amgen

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Galderma

Find clinical trials for Eczema in Charlotte, NC

Related conditions:

Eczema trials near Charlotte, NC, USA:

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden (ADsolve)

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Find clinical trials for Eczema in .css-epvm6{white-space:nowrap;}Charlotte, NC

Related conditions:

Eczema trials near Charlotte, NC, USA:

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden (ADsolve)

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Find clinical trials for Eczema in Charlotte, NC